Compare Credo Technology Group Holding Ltd (CRDO) vs Mesoblast Limited (MESO) Price & Performance

CRDO trades at $213.95, down 2.75% today but maintains strong technical support near $214. The company demonstrates exceptional fundamental performance with 114.7% YoY revenue growth and 33.83% net margins. Recent earnings beats and bullish analyst consensus at 87.5% buy ratings support the positive outlook. Technical indicators show bullish moving averages while oscillators remain neutral, with key support at $204 and resistance at $222.

CRDO presents compelling growth potential driven by AI infrastructure demand, with consensus price target of $267.33 offering 25% upside. Risks include premium valuation (P/E 74.6) and customer concentration, but strong cash flow generation and expanding optical business provide fundamental support. The stock's recent pullback may offer entry opportunity for growth investors.

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.